Aadi Bioscience, Inc.

NAS:AADIHealthcare

——At close · Market cap —

AADI · Income statement · TradingHolo

USD millions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	YoY
Revenue	14.0	1.1	15.2	24.4	26.0	7.1	−72.5%
Cost of revenue	0.2	0.3	1.3	2.8	3.0	0.0	−100.0%
Gross profit	13.8	(18.6)	13.9	21.5	23.0	0.0	−100.0%
Research & development	15.0	19.7	32.7	48.9	51.0	91.0	+78.3%
Selling, general & administrative	2.1	18.5	40.2	44.5	36.7	29.8	−18.8%
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—
Operating expenses	17.0	92.7	72.8	93.5	90.4	121.5	+34.4%
Operating income	(2.5)	(111.2)	(59.0)	(71.9)	(67.5)	(114.4)	−69.6%
Interest expense	0.8	0.7	0.2	0.2	0.2	0.0	−100.0%
Interest income	0.0	0.0	2.4	6.4	3.9	6.2	+58.8%
Other income / expense	(0.9)	1.1	2.2	6.2	3.8	93.8	+2390.2%
Pre-tax income	(3.5)	(110.1)	(60.5)	(65.8)	(63.7)	(20.6)	+67.7%
Income tax	0.0	0.0	0.0	0.0	0.0	0.0	—
Net income	(3.5)	(110.1)	(60.5)	(65.8)	(63.7)	(20.6)	+67.7%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	(26.34)	(12.41)	(2.69)	(2.44)	(2.36)	(0.03)	+98.6%
EPS, diluted (per share)	(0.51)	(12.41)	(2.69)	(2.44)	(2.36)	(0.03)	+98.6%
EBITDA	(2.5)	(109.1)	(60.1)	(65.4)	(64.6)	(114.4)	−77.0%
Depreciation & amortization	0.2	0.3	0.2	0.2	0.2	0.0	−100.0%
Weighted average shares (shares)	169,490	8,923,369	22,511,237	26,917,967	26,987,723	618,867,650	+2193.1%
Weighted average diluted shares (shares)	169,490	8,923,369	22,511,237	26,917,967	27,029,942	618,867,650	+2189.6%
Gross margin	98.7%	−1,656.3%	91.2%	88.5%	88.4%	0.0%	−88.4 pts
Operating margin	−18.2%	−9,930.1%	−387.5%	−295.4%	−259.6%	−1,601.1%	−1341.5 pts
Net margin	−24.8%	−9,829.5%	−397.7%	−270.0%	−245.1%	−288.3%	−43.1 pts

USD millionsUpdated Thu 7 May ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.